Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
WallachBeth Capital Upgrades DepoMed Inc (DEPO) to Buy
November 11, 2015 7:34 AM ESTWallachBeth Capital upgraded DepoMed Inc (NASDAQ: DEPO) from Hold to Buy with a price target of $33.00.
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $21.21 yesterday.
... MoreDepomed (DEPO) Reports 3Q EPS Beat; Janney Capital Reiterates Buy
November 10, 2015 9:25 AM ESTJanney Capital reiterated a Buy rating and $35.00 price target on DepoMed Inc (NASDAQ: DEPO) following the company's 3Q earnings report. DEPO reports $104.9 mln in revenues and non-GAAP adjusted EPS of $0.33, easily beating consensus estimates of $$101.64 mln and non-GAAP adjusted earnings of $0.19 per share.
Analyst... More
Depomed (DEPO) Tops Q3 EPS by 14c
November 9, 2015 4:04 PM ESTDepomed (NASDAQ: DEPO) reported Q3 EPS of $0.33, $0.14 better than the analyst estimate of $0.19. Revenue for the quarter came in at $105 million versus the consensus estimate of $101.64 million.
Opportunities for Sustained Growth·
NUCYNTA is strongly positioned... More